AC
AGIO icon

Armistice Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Armistice Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.1M Sell
2,400,000
-316,000
-12% -$9.59M 1.09% 11
2026
Q1 		$91.9M Sell
2,716,000
-320,000
-11% -$9.07M 1.63% 10
2025
Q4 		$82.6M Buy
3,036,000
+2,272,000
+297% +$79.7M 0.98% 13
2025
Q3 		$30.7M Sell
764,000
-404,000
-35% -$15.2M 0.45% 31
2025
Q2 		$38.8M Sell
1,168,000
-880,000
-43% -$26.7M 0.67% 22
2025
Q1 		$60M Sell
2,048,000
-216,304
-10% -$7.18M 0.9% 14
2024
Q4 		$74.4M Buy
2,264,304
+57,234
+3% +$2.69M 1.02% 18
2024
Q3 		$98.1M Buy
2,207,070
+127,919
+6% +$5.81M 1.57% 10
2024
Q2 		$89.7M Sell
2,079,151
-884,849
-30% -$31.9M 1.13% 9
2024
Q1 		$86.7M Sell
2,964,000
-560,000
-16% -$15M 1.15% 10
2023
Q4 		$78.5M Buy
3,524,000
+200,000
+6% +$4.48M 1.07% 12
2023
Q3 		$82.3M Buy
3,324,000
+68,000
+2% +$1.8M 1.26% 7
2023
Q2 		$92.2M Sell
3,256,000
-204,000
-6% -$5.08M 1.33% 9
2023
Q1 		$79.5M Buy
3,460,000
+710,000
+26% +$18.9M 1.14% 18
2022
Q4 		$77.2M Buy
2,750,000
+826,000
+43% +$23.3M 1.35% 17
2022
Q3 		$54.4M Buy
+1,924,000
New +$51.6M 0.94% 27

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Armistice Capital's AGIO Position: Q2 2026 in Review

Armistice Capital reduced its Agios Pharmaceuticals (AGIO) stake by 12% in Q2 2026, selling an estimated $9.59M and leaving 2,400,000 shares worth $89.1M. The position accounts for 1.09% of the portfolio, ranked #11.

Armistice Capital first reported a position in AGIO in Q3 2022 and has held it in 16 quarters since. The position peaked at $98.1M in Q3 2024. 239 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Armistice Capital held 2,400,000 shares of Agios Pharmaceuticals worth $89.1M as of Q2 2026.
  • Armistice Capital sold 316,000 Agios Pharmaceuticals shares in Q2 2026, an estimated $9.59M.
  • Agios Pharmaceuticals made up 1.09% of Armistice Capital's portfolio in Q2 2026, its #11 holding.
  • Armistice Capital first reported a position in Agios Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • Armistice Capital's Agios Pharmaceuticals position peaked at $98.1M in Q3 2024.
  • 239 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.